Barclays analyst Eliana Merle lowered the firm’s price target on Regenxbio (RGNX) to $12 from $37 and keeps an Overweight rating on the shares. The firm thinks further updates on FDA interactions and clarity on the regulatory pathway in Duchenne muscular dystrophy will be needed for investors to get more confident on RGX-202.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Midday Fly By: Cisco reports Q3 beat, Chinese firms cleared to buy Nvidia chips
- Regenxbio reports Q1 EPS ($1.72) vs. 12c last year
- Regenxbio expects cash, equivalents to fund operations into early 2027
- Regenxbio’s RGX-202 shows efficacy in Phase 3 Duchenne trial
- RegenXBio Advances RGX-202 With Positive Phase III Results